Drug Update Quizz

10
Created on
BTK inhibitor

Ibrutinib - an oral Bruton's tyrosine kinase (BTK) inhibitor is currently (oct 2022) not approved for treatment of :-

Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD). It is not approved for DLBCL.

Change/Click on page numbers below for next Question